Eiger BioPharmaceuticals Inc expected to post a loss of 55 cents a share - Earnings Preview

Eiger Biopharmaceuticals

04/08/2021 24:16

* Eiger BioPharmaceuticals Inc  EIGR.OQ   EIGR.O  is expected
to show a rise in quarterly revenue when it reports results on
August 5. 
* The Palo Alto, California-based company is expected to report
revenue of $2.154 million, according to the mean estimate from 5
analysts, based on Refinitiv data.  
​* Refinitiv's mean analyst estimate for Eiger
BioPharmaceuticals Inc is for a loss of 55 cents per share. For
the same quarter last year, the company reported a loss of 60
cents per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Eiger
BioPharmaceuticals Inc is $27​, about 70.9% above​ its last
closing price of $7.87. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  0.05        -0.02      -0.51     Missed  -2,061
 Dec. 31 2020  0.14        0.25       -0.57     Missed  -325.4
 Sep. 30 2020  -0.55       -0.59      -0.52     Beat    11.6​
 Jun. 30 2020  -0.70       -0.71      -0.60     Beat    15.9
 Mar.          -0.74​      -0.80      -0.62     Beat    22.8​
 31​ 2020​                                              
 Dec. 31 2019  -0.77       -0.43      -0.68     Missed  -58​
 Sep. 30 2019  -0.75       -0.75      -0.76     Missed  -1.6
 Jun. 30 2019  -0.75       -0.74      -0.75     Missed  -0.8
 This summary was machine generated August 3 at 23:16 GMT.  All
figures in US dollars unless otherwise stated